Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

Literature DB >> 3236759

Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

I Walter-Sack¹, M Eichelbaum, J X de Vries, E Weber.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1988 PMID： 3236759 DOI： 10.1007/bf01711926

Source DB: PubMed Journal: Klin Wochenschr ISSN： 0023-2173

× No keyword cloud information.

9 in total

1. Analysis of benzbromarone in human plasma and urine by high-performance liquid chromatography and gas chromatography-mass spectrometry.

Authors: J X de Vries; I Walter-Sack; A Ittensohn
Journal: J Chromatogr Date: 1987-07-03

Review 2. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].

Authors: M Eichelbaum
Journal: Internist (Berl) Date: 1983-03 Impact factor: 0.743

Review 3. Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors: M Eichelbaum
Journal: Clin Pharmacokinet Date: 1982 Jan-Feb Impact factor: 6.447

4. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors: M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal: Clin Pharmacol Ther Date: 1982-02 Impact factor: 6.875

5. Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.

Authors: I Walter-Sack; J X de Vries; A Ittensohn; M Kohlmeier; E Weber
Journal: Klin Wochenschr Date: 1988-02-15

6. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors: M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal: Eur J Clin Pharmacol Date: 1979-09 Impact factor: 2.953

7. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Authors: M Eichelbaum; L Bertilsson; J Säwe
Journal: Br J Clin Pharmacol Date: 1983-03 Impact factor: 4.335

Review 8. Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors: D W Clark
Journal: Drugs Date: 1985-04 Impact factor: 9.546

9. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors: F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal: Nature Date: 1988-02-04 Impact factor: 49.962